Image

Global Acute Hepatic Porphyria Treatment Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

Global Acute Hepatic Porphyria Treatment Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Dec 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Acute Hepatic Porphyria Treatment Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 3.72 Million
Diagram Market Size (Forecast Year) USD 5.50 Million
Diagram CAGR %

Major Markets Players

  • Teva Pharmaceutical Industries Ltd
  • Apotex
  • Pfizer
  • H. Lundbeck A/S
  • Lilly

Global Acute Hepatic Porphyria Treatment Market, By Types (Acute Intermittent Porphyria (AIP), Hereditary Coproporphyria (HCP) and Others), Treatment (Medications, Caloric Deprivation, Dehydration and Others), Route of Administration (Oral, Parenteral and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Acute Hepatic Porphyria Treatment Market

 Acute Hepatic Porphyria Treatment Market Analysis and Size

As per the NCBI, the global occurrence of acute hepatic porphyria is anticipated to vary from one in 500 to one in 50,000 individuals. Acute hepatic porphyria (AHP) is one of the types of hepatic porphyria. The incidence of clinical acute hepatic porphyria is stated to be around 5 to 10 per 100,000 individuals. It is witnessed that the persistent increase in research grants and R&D expenditures from government and other pharma companies to boost the development of rare disease drugs that would change the scenario of porphyrias treatment.

Data Bridge Market Research analyses a growth rate in acute hepatic porphyria treatment market in the forecast period 2023-2030. The expected CAGR of acute hepatic porphyria treatment market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 3.72 million in 2022, and it would grow upto USD 5.5 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Acute Hepatic Porphyria Treatment Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023-2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Types (Acute Intermittent Porphyria (AIP), Hereditary Coproporphyria (HCP) and Others), Treatment (Medications, Caloric Deprivation, Dehydration and Others), Route of Administration (Oral, Parenteral and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Teva Pharmaceutical Industries Ltd (Israel), Apotex Inc (Canada), Pfizer Inc (U.S.), H. Lundbeck A/S (Denmark), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Siemens Healthcare GmbH (Germany.), ACON Laboratories, Inc. (U.S.), Danaher. (U.S.), ARKRAY, Inc (Japan), Abbott (U.S.), Alnylam Pharmaceuticals, Inc(U.S.), Boston Scientific Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Recordati Rare Diseases Inc (Italy)

Market Opportunities

  • Growing Demand of Different Treatment Methods

Market Definition

Acute hepatic porphyria is a group of inherited diseases that are genetically different in nature; thoough, they are caused because of overproduction of heme precursors. The clinical symptoms include chest pain, vomiting, muscles pain, nausea, weakness and others. Porphyrias treatment may include evading the triggers, consumption of medicines to relieve symptoms, receiving heme through a vein, or sometimes having blood drawn to decrease iron in the body. Currently, there is no proper cure for this condition

Acute Hepatic Porphyria Treatment Market Dynamics

Drivers

There are numerous diagnostic tests that are boosting the demand of the market. Genetic testing is the primary standard test for diagnosing this condition. A genetic test can check if the person has one gene mutation that can cause AHP. It can also tell what type of AHP the patient have and how serious the enzyme deficiency is. A genetic test uses a sample of your blood or saliva. Thus, it increases the demand of the treatment drugs.  

  • Growing Incidences Of Acute Hepatic Porphyria

As per the records of NCBI, the global incidence of acute hepatic porphyria is estimated to range from one in 500 to one in 50,000 individuals. In most of the regions, acute intermittent porphyria (AIP) is the most common, and ALA dehydratase-deficiency porphyria (ALAD) is the least common. The incidence of clinical AIP is witnessed to be around 5 to 10 per 100,000 individuals, and the incidence of genetic mutations of AIP is around one in 1675 individuals. This high rate of incidence is likely to drive the demand for the market.

Opportunities

  •  Growing Demand of Diverse Treatment Methods

There are several treatment methods that are aiding in boosting the growth of the market. Panhematin is the only commercially available heme therapy in the U.S. for this condition. People suffering from severe porphyric attacks are treated with heme given by vein. If porphyrias treatment is postponed, then recovery takes longer and nerve damage may be long-lasting. Additionally, a high carbohydrate diet and intravenous glucose therapy for mild attacks are generally advised for porphyrias treatment. Liver transplantation is suggested for acute intermittent porphyria.

 Restraints/Challenges

  • Discontinuation of Drug Trials

The drug development for the disease has faced foremost obstacles as numerous therapies have failed to reveal efficacy or were associated with major toxicity. Therefore, this hampers the growth of the market.

This acute hepatic porphyria treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acute hepatic porphyria treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Acute Hepatic Porphyria Treatment Market Scope

The acute hepatic porphyria treatment market is segmented on the basis of treatment, type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

  • Acute Intermittent Porphyria (AIP)
  • Hereditary Coproporphyria (HCP)
  • Others

Treatment

  • Medications
  • Caloric Deprivation
  • Dehydration
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

 Acute Hepatic Porphyria Treatment Market Regional Analysis/Insights

The acute hepatic porphyria treatment market is analyzed and market size insights and trends are provided by treatment, type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the acute hepatic porphyria treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific will be expecting positive growth for acute hepatic porphyria treatment market throughout the forecasted period due to growing awareness among the population and increase in patient population.

North America dominates the market due to well-defined reimbursement policies from several public and private health insurance firms that help provide patients easy access of diagnosis and wide R&D activities. In the U.S., about 5,000 people experience one or more of acute hepatic porphyria attacks yearly.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Acute Hepatic Porphyria Treatment Market Share Analysis

The acute hepatic porphyria treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acute hepatic porphyria treatment market.

Key players operating in the acute hepatic porphyria treatment market include:

  • Teva Pharmaceutical Industries Ltd (Israel)
  • Apotex Inc (Canada)
  • Pfizer Inc (U.S.)
  • H. Lundbeck A/S (Denmark)
  • Lilly (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Siemens Healthcare GmbH (Germany)
  • ACON Laboratories, Inc. (U.S.)
  • Danaher. (U.S.)
  • ARKRAY, Inc (Japan)
  • Abbott (U.S.)
  • Alnylam Pharmaceuticals, Inc (U.S.)
  • Boston Scientific Corporation (U.S.)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • Recordati Rare Diseases Inc (Italy)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Acute Hepatic Porphyria Treatment Market is projected to grow at a CAGR of 5.0% during the forecast period by 2030.
The future market value of the Acute Hepatic Porphyria Treatment Market is expected to reach USD 5.5 million by 2030.
The major players in the Acute Hepatic Porphyria Treatment Market are Teva Pharmaceutical Industries Ltd (Israel), Apotex Inc (Canada), Pfizer Inc (U.S.), H. Lundbeck A/S (Denmark), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), etc.
The countries covered in the Acute Hepatic Porphyria Treatment Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, etc.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials